ClinicalTrials.gg
WithdrawnNCT05233410TRuE-CHE2Updated Nov 10, 2022

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

A Phase 3 interventional study of Ruxolitinib cream and Vehicle in Chronic Hand Eczema (CHE), sponsored by Incyte Corporation. Withdrawn at 39 sites in 7 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-11-10.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business decision; no safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Eczema by Incyte Corporation — 2 open to participants now, 2 under way, none of them phase 3. Eczema · Incyte Corporation.

Started
2023
with 4 others
Phase 3
6 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Eczema by Incyte Corporation, this one is one of 5 that started in 2023, is one of 6 in phase 3, and was the 5th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

2 of the 10 studies in Eczema by Incyte Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Eczema by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

03

Conditions studied

  • Chronic Hand Eczema (CHE)

Keywords

  • eczema
  • hand eczema
  • dermatitis
  • skin disease
  • JAK inhibitor
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting > 3 months or ≥ 2 flares within the previous 12 months.
  • Screening and baseline IGA-CHE 3 or 4.
  • Baseline CHE-related Itch NRS ≥ 4.
  • Recent history (within the past 1 year of baseline) of inadequate response to treatment with topical (TCS), topical calcineurin inhibitors (TCI), or oral alitretinoin; or intolerance or to TCS or TCI or oral alitretinoin.
  • Willingness to avoid pregnancy or fathering children based on the criteria below.

Exclusion criteria

Exclusion Criteria:

  • Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
  • Participants who have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline.
  • Participants with concurrent conditions and history of other diseases such as other active skin disease or infection on the hands; ; chronic or acute infection requiring systemic treatments; active acute skin infection; other concomitant skin conditions that may interfere with study assessments or compromise participant safety; other types of eczema; chronic asthma requiring high dose of inhaled ; current or history of or C virus infection.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Laboratory values outside of the protocol-defined criteria.
  • Use of protocol-defined treatments within the indicated before baseline.
  • Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.
  • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.

    Drug: Ruxolitinib cream

  • Placebo comparator
    Vehicle

    Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.

    Drug: Vehicle

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB18424 cream

  • DrugVehicle

    Vehicle cream is a topical formulation applied as a thin film to affected areas.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants achieving Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS)

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants with a ≥ 4-point improvement in chronic hand eczema (CHE)-related Itch Numerical Rating Scale (NRS) score

    The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable) on a daily basis.

    Time frame: Baseline to Week 16

  2. Percentage of Participants with a ≥ 2-point improvement in CHE-related Skin Pain NRS score

    The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Baseline to Week 16

  3. Change from baseline in the mTLSS (modified Total Lesion Symptom Score

    The mTLSS is a validated tool for assessing hand eczema. The scale quantifies the 7 features (erythema, scaling, hyperkeratosis/lichenification, vesiculation, oedema, fissures, and pruritus/pain) of HE (0 = none, 1 = mild, 2 = moderate, and 3 = severe).

    Time frame: Up to Week 32

  4. Percentage of Participants achieving an IGA CHE-TS

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: Up to Week 32

  5. Change from baseline in CHE-related Itch NRS score (weekly average)

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: Up to Week 32

  6. Change from baseline in CHE-related Skin Pain NRS score (weekly average)

    The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and participants will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Up to Week 32

  7. Time to ≥ 4-point improvement in CHE-related Itch NRS score

    The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and participants will rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable) on a daily basis.

    Time frame: Up to Week 32

  8. Time to ≥ 2-point improvement in CHE-related Skin Pain NRS score

    The Pain NRS is a validated, self-reported, instrument for measurement of itch intensity and participants will rate the intensity of their pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) on a daily basis.

    Time frame: Up to Week 32

  9. Percentage change in Hand Eczema Severity Index (HECSI)

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales.

    Time frame: Baseline to Week 16

  10. Percentage of participants with HECSI-75

    HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales.

    Time frame: Weeks 2, 8, 16, 32

  11. Percentage of participants with HECSI-90

    HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales.

    Time frame: Weeks 2, 8, 16, 32

  12. Mean Patient Global Impression of Change (PGIC) score

    The Patient Global Impression of Change (PGIC) is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE and will be captured during site visits. It is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to Week 32

  13. Percentage of participants with each score on the PGIC

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE and will be captured during site visits. It is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to Week 32

  14. Percentage of participants with a score of either 1 or 2 on the PGIC

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE and will be captured during site visits. It is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to Week 32

  15. Change from baseline in Dermatology Life Quality Index (DLQI) score

    The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Up to Week 32

  16. Change from baseline in EQ-5D-5L score

    EQ-5D-5L is a is a validated, self-administered, generic, utility questionnaire wherein participants will rate their current health state based on the following criteria: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: Up to Week 32

  17. Change from baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) score

    The QOLHEQ is a validated instrument to assess disease specific Health Related Quality of Life (HRQOL) in patients suffering from hand eczema. The QOLHEQ is a disease specific instrument, thereby only assessing impairments caused by hand eczema. It consists out of 30 items which can be summarized according to four domains of HRQOL: Impairments because of (1) symptoms, (2) emotions, (3) limitations in functioning or (4) because of treatment and prevention.

    Time frame: Up to Week 32

  18. Change from baseline in Working Limitations Questionnaire (WLQ) score

    The Work Limitations Questionnaire (WLQ) is a patient self-rated scale designed to assess on the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5- point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The WLQ Productivity Loss Score is derived from the Global Productivity Index, which is calculated as a weighed sum of the 4 dimensions. Reduction in WLQ Productivity Loss score indicates less work limitation and represents the estimated percentage of productivity loss in the past two weeks due to presenteeism relative to a healthy benchmark sample. WLQ Productivity Loss Score ranges from 0% to 24.9%. Higher percent productivity loss reflects more severe work limitations.

    Time frame: Up to Week 32

  19. Change from baseline in Work Productivity and Activity Impairment Questionnaire Specific Health Problem v2.0 in Chronic Hand Eczema (WPAI-SHP-CHE)

    The WPAI:SHP questionnaire assesses both work productivity through absenteeism (i.e., work time missed), presenteeism (i.e., impairment at work or reduced on-the-job effectiveness), and work productivity loss, as well as daily activity impairment (e.g., work around the house, shopping, exercising, childcare, studying) attributable to excess weight. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Negative numbers indicate improvement from baseline.

    Time frame: Up to week 32, followed by 30 days follow-up.

  20. Number of Participants with Treatment Emergent Adverse Events (TEAE)

    Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to 40 weeks

07

Study locations

39 sites
  • University of Alabama Hospital
    Birmingham, Alabama 35249, United States
  • Marvel Clinical Research LLC
    Huntington Beach, California 92647, United States
  • Advanced RX Clin Research
    Westminster, California 92683, United States
  • Advanced Rx Clinical Research
    Westminster, California 92683, United States
  • Forcare Clinical Research
    Tampa, Florida 33613, United States
  • Midwest Allergy Sinus Asthma, Sc
    Springfield, Illinois 62704, United States
  • The Indiana Clinical Trials Center Ictc
    Plainfield, Indiana 46168, United States
  • Delricht Research
    Baton Rouge, Louisiana 70809, United States
  • Jubilee
    Las Vegas, Nevada 89106, United States
  • Onsite Clinical Solutions, Llc Charlotte Central Office
    Charlotte, North Carolina 28277, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Froedtert & Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Medical Center Unimed Eood
    Sevlievo, 05402, Bulgaria
  • Dcc 'Alexandrovska', Eood
    Sofia, 01431, Bulgaria
  • Medical Center Hera Eood
    Sofia, 01510, Bulgaria
  • Dcc Xxviii
    Sofia, 01592, Bulgaria
  • Mc 'Synexus - Sofia', Eood
    Sofia, 01784, Bulgaria
  • Dcc 'Alexandrovska', Eood
    Sofia, 1431, Bulgaria
  • Dr. Chih-Ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Simcomed Health Ltd
    Barrie, Ontario L4M 1G7, Canada
  • Xlr8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Fakultni Nemocnice U Sv. Anny V Brne
    Brno, 656 91, Czechia
  • Clintrial SRO
    Praha 10, 100 00, Czechia
  • Krajska Zdravotni A.S. - Masarykova Nemocnice V Usti Nad Labem O.Z.
    Usti Nad Labem, 401 13, Czechia
  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte
    Berlin, 10117, Germany
  • Universitaetsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • Derma-Study-Center Friedrichshafen Gmbh
    Friedrichshafen, 88045, Germany
  • Dermatologikum Hamburg Gemeinschaftspraxis Gbr
    Hamburg, 20354, Germany
  • Universitaetsklinikum Schleswig Holstein - Campus Luebeck
    Luebeck, 23538, Germany
  • Gemeinschaftspraxis
    Mahlow, 15381, Germany
  • Beldio Research Gmbh
    Memmingen, 87700, Germany
  • Dermatologische Klinik Der Technischen Universitat Munchen
    Muenchen, 80802, Germany
  • Klifos - Klinische Forschung Osnabrück
    Osnabruck, 49074, Germany
  • Etg Warszawa
    Warsaw, 02-777, Poland
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Clinica Dermomedic
    Madrid, 28001, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario Quironsalud Madrid
    Madrid, 28223, Spain
  • Hospital de Manises
    Valencia, 46940, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2023; primary completion for Apr 2024, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2022
First posted
Feb 10, 2022
StartEst.
Jan 31, 2023
Primary completionEst.
Apr 25, 2024
CompletionEst.
Sep 22, 2024
Last update
Nov 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05233410
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Jan 31, 2023 (estimated)
Primary completion
Apr 25, 2024 (estimated)
Completion
Sep 22, 2024 (estimated)
Last update
Nov 10, 2022

Study contacts

Haq Nawaz, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion